logo

46.38

46.38 (0.99%)

As of Mar 06, 2024

Soleno Therapeutics Inc [SLNO]

Source: 

Company Overview

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.Our lead drug,Diazoxide Choline Extended-Release tablets (DCCR),is apotent ATP-sensitive potassium (KATP)channel activator. The KATPchannel plays a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in many forms of hyperphagic obesity, including Prader-Willi syndrome (PWS), these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state.

CountryUnited States
Headquartersredwood citycalifornia
Phone Number650-213-8444
Industry
manufacturing
CEOAnish Bhatnagar
Websitehttps://www.fpwr.org

Related Stories